Jane Street
IMPL

Jane Street’s Impel Pharmaceuticals Inc. Common Stock IMPL Stock Holding History

Jane Street’s Portfolio IMPL Stock Details IMPL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-13,147
Closed -$49.3K – 10269
2022
Q4 		$49.3K Buy
+13,147
New +$47.9K ﹤0.01% 8370

Other funds holding IMPL

KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
NA
NVP Associates Menlo Park, California $176M AUM 208.78% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LM
Lasry Marc $15.1M AUM 10.39% 1-Year Est. Return
DA
DCF Advisers Greenwich, Connecticut $375M AUM 72.65% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

Jane Street's IMPL Position: Q1 2023 in Review

Jane Street sold out of Impel Pharmaceuticals Inc. Common Stock (IMPL) in Q1 2023, closing a stake of 13,147 shares — an estimated $49.3K sold.

Jane Street first reported a position in IMPL in Q4 2022 and held it in 1 quarter. The position peaked at $49.3K in Q4 2022. 32 funds tracked by Wall St. Rank hold IMPL as of Q1 2023.

  • Jane Street reported no remaining Impel Pharmaceuticals Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
  • Jane Street sold 13,147 Impel Pharmaceuticals Inc. Common Stock shares in Q1 2023, an estimated $49.3K.
  • Jane Street first reported a position in Impel Pharmaceuticals Inc. Common Stock in Q4 2022 and held it in 1 quarter.
  • Jane Street's Impel Pharmaceuticals Inc. Common Stock position peaked at $49.3K in Q4 2022.
  • 32 funds tracked by Wall St. Rank held Impel Pharmaceuticals Inc. Common Stock as of Q1 2023.

Based on Jane Street's 13F filing for Q1 2023, filed 16 May 2023.